patent/SG-178779-A1

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-178779-A1

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
filingDate	2008-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_508781bc36537480d31044ee83ad7266 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ede99392cd4f129ede96bfc9de5f47f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a11eca8e9680b9a546c8a0195efc677 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b115218ba8cdef0817697cd8052d86b
publicationDate	2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	SG-178779-A1
titleOfInvention	Fast dissociating dopamine 2 receptor antagonists
abstract	Abstract FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTSThe present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, forexample schizophrenia, by exerting an antipsychotic effect without motor side effects.No suitable figure
priorityDate	2007-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457574860 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681

Total number of triples: 32.